| Zacks Company Profile for Xeris Biopharma Holdings, Inc. (XERS : NSDQ) |
|
|
| |
| • Company Description |
| Xeris Biopharma Holdings is a biopharmaceutical company. It involved in developing and commercializing therapies for patient in endocrinology, neurology and gastroenterology. The company's principal product includes Gvoke(R), a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and Keveyis(R), the first and only FDA-approved therapy for primary periodic paralysis. Xeris Biopharma Holdings, formerly known as Xeris Pharmaceuticals Inc., is headquartered in Chicago, IL.
Number of Employees: 394 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $5.27 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,964,263 shares |
| Shares Outstanding: 156.38 (millions) |
| Market Capitalization: $824.15 (millions) |
| Beta: 0.66 |
| 52 Week High: $6.07 |
| 52 Week Low: $2.10 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
19.23% |
14.77% |
| 12 Week |
28.22% |
7.85% |
| Year To Date |
55.46% |
45.58% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
John Shannon - Chief Executive Officer
Marla Persky - Chairperson
Steven M. Pieper - Chief Financial Officer
B.J. Bormann - Director
Ricki Fairley - Director
|
|
Peer Information
Xeris Biopharma Holdings, Inc. (GSAC)
Xeris Biopharma Holdings, Inc. (CASI)
Xeris Biopharma Holdings, Inc. (ALCD.)
Xeris Biopharma Holdings, Inc. (OMNN)
Xeris Biopharma Holdings, Inc. (CGPI.)
Xeris Biopharma Holdings, Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 98422E103
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
|
|
Share - Related Items
Shares Outstanding: 156.38
Most Recent Split Date: (:1)
Beta: 0.66
Market Capitalization: $824.15 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $0.00 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-0.07 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 4.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/14/25 |
|
|
|
| |
